Profile: UCB S.A. is a biopharmaceutical company. Our products include keppra®, nootropil®, xyrem®, vimpat®, neupro®, cimzia®, xyzal®, zyrtec®, tussionex™, lortab™ and innovair®. Keppra® is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Nootropil® is a cerebral function regulator, used to treat adults and the elderly people. It belongs to the family of cognition enhancing medicines called Nootropics. It was first marketed for the treatment of vertigo and events associated with ageing. Its main indications are in the area of psycho-organic syndromes or cognitive decline & cortical myoclonus. Deponit® is indicated for the treatment of coronary artery disease, angina pectoris and pulmonary hypertension. Isoket® is used for the treatment of angina and heart failure. We provide xyrem® which is a drug for narcolepsy with cataplexy in adult patients. Innovair® is indicated in the regular treatment of asthma. Tussionex™ is approved for the relief of cough & upper respiratory symptoms associated with allergy or cold in adults. Xyzal® is an antihistamine for the symptomatic treatment of allergic rhinitis, including persistent allergic rhinitis & chronic idiopathic urticaria. Neupro® is available under the form of a transdermal patch for the treatment of Parkinson's disease. Zyrtec® is an antihistamine treatment for the symptoms of perennial allergic rhinitis, seasonal allergic rhinitis and chronic idiopathic urticaria.